Mallinckrodt to add another opioid to its arsenal for pain management
Mallinckrodt, the largest U.S. supplier of opioid pain medications, plans to purchase Xanodyne Pharmaceuticals’ Roxicodone (oxycodone hydrochloride tablets USP) in 5-mg, 15-mg, and 30-mg dosage strengths.
Mallinckrodt, the largest U.S. supplier of opioid pain medications, plans to purchase Xanodyne Pharmaceuticals’ Roxicodone (oxycodone hydrochloride tablets USP) in 5-mg, 15-mg, and 30-mg dosage strengths. The immediate-release formulation is indicated for the management of moderate to severe pain when use of an opioid is appropriate.
“We are excited about this agreement (with Xanodyne) as it complements our existing portfolio of opioids and leverages our pain management expertise,” said Mark Trudeau, president, Pharmaceuticals, Mallinckrodt, in a press release. “More importantly, we are committed to safe and effective use of all of our products along with ensuring access for all patients in need of pain treatment.”
Mallinckrodt, the pharmaceuticals business of Covidien, also manufactures hydromorphone HCl (Exalgo) extended-release tablets (CII) and diclofenac sodium topical solution (Pennsaid) 1.5%. The company also is a leading producer of bulk acetaminophen.
In mid-2013, Covidien plans to spin off Mallinckrodt into its own stand-alone company, according to a Business Wire release.
Pharmacists Play Unique Role in Advancing Health Equity for Patients With Chronic Disease
December 7th 2023A new study, outlined in a poster at ASHP Midyear 2023, identified 3 key themes associated with the ways in which pharmacists are positioned to advance health equity for patients with chronic diseases.
Assessing Financial Impacts of Pharmacist-Led Interventions in Pediatric Ambulatory Care
December 5th 2023According to a poster abstract presented at the ASHP Midyear Clinical Meeting & Exhibition, specialty pharmacy services were used for a variety of conditions that have been reported in adult populations.
